VIB193 / Vibrant Therapeutics - LARVOL DELTA

VIB193, the first TCE prodrug targeting CAIX for the treatment of solid cancer (SITC 2025) - "Background The approval of Catumaxomab, the first T cell engager (TCE) for solid tumors in 2009 brought hope that TCEs could achieve both high response rates and durable benefits in solid tumor patients. However, over the following 15 years, efforts to develop TCEs for solid tumors have led to the approval of only two additional drugs: the TCR-based Tebentafusp and the antibody-based Tarlatamab...These rendered VIB193 a high therapeutic window not observed with conventional TCEs. It is noteworthy that, due to high TCE's high potency, VIB193 was able to achieve complete responses (per mRECIST criteria) at low doses.Conclusions VIB193 holds promise for the treatment of a wide range of solid tumors and represents a significant step forward toward overcoming the challenges traditionally associated with TCEs for solid tumors.Ethics Approval Ethical committee approval ID number for the animal work 20250206C02, Guangzhou, China."

Lung Cancer • Oncology • Solid Tumor • CA9